Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
ALLERGAN AUSTRALIA PTY LIMITED
🇦🇺
Australia
Country
🇦🇺
Australia
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News
Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines
Phase 4
Completed
Conditions
Glabellar Frown Lines
Interventions
Drug: normal saline (placebo)
Biological: botulinum toxin Type A
Subscribe
First Posted Date
2011-07-12
Last Posted Date
2012-09-25
Lead Sponsor
Allergan
Target Recruit Count
40
Registration Number
NCT01391312
Subscribe
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines
Not Applicable
Completed
Conditions
Facial Rhytides
Glabellar Frown Lines
Interventions
Biological: botulinum toxin Type A
Drug: Normal Saline
Subscribe
First Posted Date
2011-07-12
Last Posted Date
2019-04-17
Lead Sponsor
Allergan
Target Recruit Count
175
Registration Number
NCT01391299
Subscribe
Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis
Phase 3
Completed
Conditions
Eyelash Hypotrichosis
Interventions
Drug: bimatoprost solution 0.03%
Drug: bimatoprost vehicle solution
Subscribe
First Posted Date
2011-07-12
Last Posted Date
2019-07-08
Lead Sponsor
Allergan
Target Recruit Count
173
Registration Number
NCT01391273
Subscribe
Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis
Phase 3
Completed
Conditions
Eyelash Hypotrichosis
Interventions
Drug: bimatoprost vehicle solution
Drug: bimatoprost solution 0.03%
Subscribe
First Posted Date
2011-07-12
Last Posted Date
2019-07-08
Lead Sponsor
Allergan
Target Recruit Count
36
Registration Number
NCT01391286
Subscribe
Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity
Completed
Conditions
Muscle Spasticity
Interventions
Biological: botulinum toxin Type A
Subscribe
First Posted Date
2011-07-04
Last Posted Date
2014-02-03
Lead Sponsor
Allergan
Target Recruit Count
108
Registration Number
NCT01387074
Subscribe
Effect of Botulinum Toxin Type A on Swallowing in Patients With Cervical Dystonia
Phase 4
Completed
Conditions
Torticollis
Interventions
Biological: botulinum toxin Type A
Subscribe
First Posted Date
2011-06-29
Last Posted Date
2011-06-29
Lead Sponsor
Allergan
Target Recruit Count
28
Registration Number
NCT01384214
Subscribe
Retrospective Study of Patients With Spasticity in the Spanish Population
Completed
Conditions
Muscle Spasticity
Interventions
Other: No treatment
Subscribe
First Posted Date
2011-06-28
Last Posted Date
2013-11-14
Lead Sponsor
Allergan
Target Recruit Count
235
Registration Number
NCT01383681
Subscribe
Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia
Phase 2
Completed
Conditions
Alopecia
Baldness
Alopecia, Androgenetic
Interventions
Drug: bimatoprost Formulation A
Drug: bimatoprost Formulation B
Drug: bimatoprost Formulation C
Drug: bimatoprost vehicle solution
Drug: minoxidil 5% solution
Subscribe
First Posted Date
2011-03-29
Last Posted Date
2014-04-10
Lead Sponsor
Allergan
Target Recruit Count
307
Registration Number
NCT01325337
Subscribe
Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss
Phase 2
Completed
Conditions
Baldness
Alopecia
Interventions
Drug: bimatoprost Formulation B
Drug: bimatoprost Formulation C
Drug: bimatoprost vehicle solution
Drug: minoxidil 2% solution
Drug: bimatoprost Formulation A
Subscribe
First Posted Date
2011-03-29
Last Posted Date
2014-04-09
Lead Sponsor
Allergan
Target Recruit Count
306
Registration Number
NCT01325350
Subscribe
Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye
Phase 1
Completed
Conditions
Dry Eye Syndromes
Interventions
Drug: cyclosporine ophthalmic emulsion Formulation A
Drug: cyclosporine ophthalmic emulsion Formulation B
Drug: cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%
Drug: cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%
Drug: cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B
Subscribe
First Posted Date
2011-03-22
Last Posted Date
2015-09-07
Lead Sponsor
Allergan
Target Recruit Count
44
Registration Number
NCT01319773
Subscribe
Prev
1
31
32
33
34
35
51
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy